Committed to Ophthalmic Practices
RXQ Compounding produces several sterile medications specific to the ophthalmology clinical and surgical suite setting needs. These are produced in our new, 42,500 square foot, State-of-the-art compounding facility, within ISO-5 level hoods under cGMP standards. All batches of RXQ produced sterile products are end-product tested, which includes drug assay, endotoxin content, particulate matter, and sterility. All products are held in quarantine until these test results are received.
Popular Ophthalmology Products
RXQ Compounding produces Avastin syringes for intravitreal injection for hospital and clinical settings for the treatment of wet macular edema. We currently compound these into tuberculin syringes (without attached needle) in fill volumes of Avastin 25mg/ml – 0.1ml, 0.12ml, and 0.15ml. We work with our customers to establish standing orders and shipments of the needed quantities for clinic patient treatment. End-product testing of Avastin syringes requires approximately 3 weeks and quantities can be modified as clinic schedules vary.